Anti-Human C3b/iC3b Monoclonal Antibody (clone 3E7) -10 mg (CAT#: CB-P427-AB) Datasheet

Product Type
Antibody
Description
The monoclonal antibody 3E7 recognizes human complement C3b/iC3b and blocks the activation of other pathways (AP). The complement system plays an important role in both innate and adaptive immune responses, and can produce inflammatory and protective responses to pathogen attacks before the adaptive response occurs. There are three ways to activate complement. The classical pathway is triggered by immune complexes. Surface-bound mannan-bound lectin pathways; and all surfaces that are not specifically protected. Each produces C3 convertase, a serine protease that cleaves the central complement protein C3 and produces the main cleavage fragment C3b. C3 and C5 invertases are enzyme complexes that initiate and amplify the activity of the complement pathway and ultimately produce cytolytic MAC. After activating C3, two fragments will be generated. The smaller anaphylactoxin C3a and the larger short-lived C3b. The latter is highly reactive and can be combined with complement activating particles or immune complexes. Unlike the classic approach, AP is in a continuous activation state. AP plays an important role in tissue damage and inflammation associated with certain autoimmune diseases and ischemia-reperfusion injury. More and more evidences show that blocking AP activation can prevent or reduce certain diseases and maintain the host defense capabilities provided by CP and LP. The deposition of C3b on the cell surface can disrupt cell conditioning. Cell-bound C3b can be degraded into an inactive form, iC3b, and then degraded into C3dg. Antibody 3E7 shows enhanced specificity for C3b(i) attached to the cell surface, and can bind to cells conditioned by C3b(i) in whole blood. This antibody blocks AP based on its ability to prevent the deposition of C3b on the surface of various AP activators, and also inhibits AP-promoted lysis of rabbit red blood cells, as used in the standard AP50 test. Clone 3E7 competes with factors B and H for binding C3b opsonized substrates. The use of 3E7 has been shown to enhance the immunotherapeutic effect of rituximab. CP is not affected or enhanced by this antibody.
Disease
Infectious diseases, Nephrology
Size
100 µg
Immunogen
C3b(i)-Sepharose
Species
Human
Host
Mouse
Clonality
Monoclonal
Isotype
Mouse IgG1
Clone Number
3E7
Buffer
PBS with a concentration of at least 10 mg/ml. The endotoxin concentration is < 24 EU/mg, determined with HIT302 LAL Assay.
Application
Flow cytometry, Functional studies, Immuno fluorescence
Application Notes
The typical initial working dilution is 1:50. For functional studies, the in vitro dilution must be optimized in the user's experimental environment.
Storage Instructions
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Target
C3b/iC3b
Alternative Names
Complement component C3b; iC3b; C3c

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK